Can Chinese Phase I data from the West accelerate China drug development?

The science of ethnobridging – a way to implement cost-effective, multi-ethnic approaches to global clinical trial research and drug development.


Open PDF

Return to Insights Center

Related Insights

Video

The science and practice of ethnobridging

May 17, 2023

Podcast

Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Video

How early-stage diversity strategies can save time and budget later

Oct 3, 2023

Video

The 2024 FDA Diversity Guidance Update: What does it mean for patients, sites, sponsors and CROs

Aug 22, 2024

Blog

Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients

Sep 23, 2022

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Blog

Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity

Mar 3, 2022

Article

How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Related Insights

Video

The science and practice of ethnobridging

May 17, 2023

Podcast

Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Article

Australia: A highly attractive environment for drug development

Aug 24, 2023

Video

How early-stage diversity strategies can save time and budget later

Oct 3, 2023

Video

The 2024 FDA Diversity Guidance Update: What does it mean for patients, sites, sponsors and CROs

Aug 22, 2024

Show more